Showing 4841-4850 of 5646 results for "".
- American Academy of Ophthalmology In-Person Meeting Cancelledhttps://modernod.com/news/american-academy-of-ophthalmology-in-person-meeting-cancelled/2478008/Due to the COVID-19 pandemic, the American Academy of Ophthalmology (AAO) has cancelled its in-person annual meeting scheduled to take place in November in Las Vegas. “In light of epidemiological projections, government regulations and public health mandates to prevent the spread of
- Santen and NTC Release Results of Phase 3 Clinical Study Examining 7-Day Fixed Dose Combination of Levofloxacinhttps://modernod.com/news/santen-and-ntc-release-results-of-phase-3-clinical-study-examining-7-day-fixed-dose-combination-of-levofloxacin/2478007/Santen EMEA and NTC have announced that the results of their phase 3 clinical study, LEADER7, have been published in Eye. The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye dr
- HHS Allocates Another $4B in COVID-19 Relief Funds to Rural Facilities, Safety Net Hospitalshttps://modernod.com/news/hhs-allocates-another-4b-in-covid-19-relief-funds-to-rural-facilities-safety-net-hospitals/2478004/The Department of Health and Human Services (HHS) is allocating approximately $3 billion to safety net hospitals and another $1 billion in COVID-19 relief funds to certain rural providers and others in small metropolitan areas, according to a FierceHealthcare
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- Women in Ophthalmology (WIO) 2020 Summer Symposium Goes Virtualhttps://modernod.com/news/women-in-ophthalmology-wio-2020-summer-symposium-goes-virtual/2477999/Due to the recent rise in COVID-19 cases in Florida, Women in Ophthalmology (WIO) has decided to is move its Summer Symposium to an all-virtual platform on August 21-23, 2020. “In classic WIO fashion, we have planned an innovative meeting like no other with 24 hours of CME, scientifi
- New $1-Billion Fund Aims to Rescue “Collapsing” Antibiotic Pipelinehttps://modernod.com/news/new-1-billion-fund-aims-to-rescue-collapsing-antibiotic-pipeline/2477997/More than 20 biopharmaceutical companies on Thursday joined forces to invest nearly $1 billion in a new fund aimed at supporting the development of antibiotics to address the rapid rise of antimicrobial resistance (AMR). The AMR Action Fund, spearheaded by the International Federation of Ph
- BD Launches 15-minute Coronavirus Antigen Test, Promises Millions in Coming Monthshttps://modernod.com/news/bd-launches-15-minute-coronavirus-antigen-test-promises-millions-in-coming-months/2477994/The FDA granted an emergency authorization to a portable coronavirus antigen test developed by BD, similar to a rapid flu test, designed to allow hospitals, doctors’ offices, urgent care centers, and retail pharmacies to examine a person showing symptoms in about 15 minutes, accor
- Vision Expo West 2020 Cancelled; Virtual Offerings Plannedhttps://modernod.com/news/vision-expo-west-2020-cancelled-new-virtual-offerings-planned/2477995/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announced the decision to cancel Vision Expo West 2020, scheduled to take place in Las Vegas from September 23-26. “Over the past several months, Reed Exhibitions’ Vision Expo team and The Vision Council worked toget
- LumiThera Closes Series C Round of Financinghttps://modernod.com/news/lumithera-closes-series-c-round-of-financing/2477993/LumiThera announced it has completed its Series C financing. The company raised approximately $14 million to support further commercialization of its Valeda Light Delivery System for the treatment for dry age-related macular degeneration (AMD), to complete its LIGHTS
- Palatin Technologies Announces Reinitiation of Enrollment of Phase 2 Study With PL9643 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-reinitiation-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2477985/Palatin Technologies announced reinitiation of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After pausing patient recruitment to ensure patient safety during the initial phases of the COVID-19 pandemic, Palatin has commenced patient recruitment in